RBC-FluoGene^® Q

RBC-FluoGene^® RHD Zygosity Q

For RHD zygosity determination, a distinction must be made between DD (RHD*01/*01) and Dd (RHD*01/*01N.01) samples. The RBC-FluoGene^® RHD Zygosity Q test system is a fluorescence-based quantification of RHD exons 1 and 10 from genomic DNA for the determination of RHD zygosity by Real-time PCR. The calculation of RHD zygosity is done via ΔΔCt-value.

RBC-FluoGene^® D weak Screen Q

The D weak Screen Q test identifies the alleles RHD*01W.1, RHD*01W.2, and RHD*01W.3 classified as D positive in one reaction. With the 2nd mix, in combination with the first mix, a separation of the RHD*09 allele cluster occurs, separating the D weak type 4.0/4.1 alleles from 4.2 and 4.3.

On a 96-well plate, a screening of 96 samples for D+ alleles are possible (Mix 1 only), or 48 samples with additional separation of the RHD*09 alleles. The evaluation is performed using the Ct value calculation of the used Real-time instrument.

RBC-FluoGene^® fetal RHD Q

Fetal RHD genotyping from maternal plasma is a groundbreaking technique in prenatal diagnostics. This non-invasive method offers crucial insights into the RhD blood type status of the fetus, thereby aiding in the management of RhD alloimmunization potentially leading to hemolytic disease of the newborn (HDN). The clinical implications of fetal RHD genotyping are significant. For RhD-negative mothers carrying RhD-positive fetuses, knowledge of the fetal RhD status allows for timely interventions to prevent RhD alloimmunization.

These interventions may include administration of Rh immunoglobulin (RhIg) to suppress the maternal immune response, thus reducing the risk of HDN in subsequent pregnancies. Conversely, RhD-negative fetuses can be identified early, sparing unnecessary RhIg administration and associated costs.